Life Science Investing ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
Life Science Investing ARS Pharmaceuticals Submits Response for neffy® Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
LaFleur Minerals Provides Update on Beacon Mill Restart, Results of Annual General and Special Meeting, and Swanson Gold Deposit Exploration and Drilling Updates
